Five Years With Dolutegravir Plus Lamivudine as a Switch Strategy: Much More Than a Positive Finding
| Autor: | Andrea Giacometti, Gabriella d'Ettorre, Amedeo Capetti, William Gennari, Stefano Rusconi, Gaetana Sterrantino, Andrea Giacomelli, Vanni Borghi, Gianmaria Baldin, Alessandra Latini, Andrea De Vito, Cristina Mussini, Arturo Ciccullo, Simona Di Giambenedetto, Giordano Madeddu, Maria Vittoria Cossu |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
medicine.medical_specialty HAART Anti-HIV Agents Pyridones HIV Infections 3-Ring Settore MED/17 - MALATTIE INFETTIVE Piperazines chemistry.chemical_compound Heterocyclic Compounds Interquartile range Internal medicine HIV Seropositivity Oxazines medicine Humans Pharmacology (medical) Survival analysis Retrospective Studies business.industry HIV Lamivudine Retrospective cohort study Middle Aged dolutegravir Discontinuation Regimen Infectious Diseases Tolerability chemistry Dolutegravir RNA Female business Heterocyclic Compounds 3-Ring medicine.drug |
| Zdroj: | JAIDS Journal of Acquired Immune Deficiency Syndromes. 88:234-237 |
| ISSN: | 1525-4135 |
| Popis: | BACKGROUND Results from clinical trials and observational studies suggest that dolutegravir plus lamivudine could be an effective and well-tolerated option for simplification in HIV-1-positive patients. We aimed to assess long-time efficacy and safety in our multicenter cohort. METHODS This was a retrospective study enrolling HIV-1-infected, virologically suppressed patients switching to dolutegravir + lamivudine. We performed survival analysis to evaluate time to virological failure (VF, defined by a single HIV-RNA ≥1000 copies/mL or by 2 consecutive HIV-RNA ≥ 50 copies/mL) and treatment discontinuation (defined as the interruption of either 3TC or dolutegravir), assessing predictors via Cox regression analyses. RESULTS Seven-hundred eighty-five patients were considered for the analysis: 554 were men (70.6%), with a median age of 52 years (interquartile range 45-58 years). Estimated probabilities of maintaining virological suppression at weeks 96, 144, and 240 were 97.7% (SD ±0.6), 96.9% (SD ±0.8), and 96.4% (SD ±0.9), respectively. A non-B HIV subtype (P = 0.014) and a previous VF (P = 0.037) resulted predictors of VF. We did not observe differences in probability of VF in people living with HIV with an M184V resistance mutation (P = 0.689); however, in a deeper analysis, M184V mutation was a predictor of VF (P = 0.038) in patients with time of virological suppression |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|